Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company was founded to help stop the current coronavirus pandemic (COVID-19) and prevent the next. Pardes scientists developed a novel oral antiviral treatment for COVID-19, pomotrelvir, from concept through phase 2 testing in under three years. In addition, our research efforts have generated highly potent new chemical entities with broad spectrum pan-coronavirus activity to help better prepare for future threats. Our lead program, pomotrelvir, our research assets, and intellectual property are available for partnering while the company explores a range of strategic alternatives. Contact us here.

Learn More

Stock
Quote

Volume:

09/11/2023 5:04 PMEDT

Press
Releases

08/31/2023

Pardes Biosciences Announces Closing of Tender Offer

07/17/2023

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

05/05/2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

04/03/2023

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Webcasts

Financial Information

Document Date	Description	Form	View
02/07/2022	Filing by person(s) reporting owned shares of common stock in a public company >5%	SC 13D	View HTML 0001193125-22-029604.pdf 0001193125-22-029604.rtf 0001193125-22-029604.xls
06/29/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-034553.pdf 0001213900-21-034553.rtf 0001213900-21-034553.xls
07/09/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-036257.pdf 0001213900-21-036257.rtf
07/09/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-036367.pdf 0001213900-21-036367.rtf 0001213900-21-036367.xls
08/05/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-040397.pdf 0001213900-21-040397.rtf
08/26/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-044900.pdf 0001213900-21-044900.rtf
08/26/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-044984.pdf 0001213900-21-044984.rtf
08/27/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-045161.pdf 0001213900-21-045161.rtf
09/01/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-046132.pdf 0001213900-21-046132.rtf 0001213900-21-046132.xls
09/21/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-049099.pdf 0001213900-21-049099.rtf

Contact
IR

Send us an investor-related question using the form below.